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findings, mice lacking a functional A-type
lamin gene (Lmna) develop an EDMD-like
syndrome soon after birth and die within
6 weeks of cardiovascular disease. A
recent publication by Chen et al. (2012)
reports the remarkable finding that down-
regulation of Sun1 expression in Lmna-
deficient mice significantly extended their
life span along with amelioration of
cardiac pathology. Thus, LINC complexes
could represent viable therapeutic targets
for the treatment of certain types of stri-
ated muscle disease and perhaps other
laminopathies. The insights that Sosa
et al. now provide into the molecular
details of LINC complex assembly
suggest strategies for the design of drugs
that could interfere with SUN-KASH inter-actions. This convergence of structural
biology and mouse genetics may provide
the foundation for novel interventions in
muscular dystrophy and heart disease.
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Historically, key cellular regulators of diverse physiological processes have been uncovered
by studying the mechanisms by which chemical entities produce interesting biological pheno-
types. In this issue, Dixon et al. interrogate compounds that selectively kill oncogene-express-
ing cells, providing support for the existence of an iron-requiring, regulated form of cell death,
ferroptosis.Various forms of regulated cell death
have been identified, including apoptosis,
necroptosis, paraptosis, parthanoptosis,
pyroptosis, and autophagic cell death.
In this issue, Stockwell and colleagues
propose the existence of ferroptosis,
an iron-dependent form of cell death
(Dixon et al., 2012). Ferroptosis requires
iron-dependent production of reactive
oxygen species (ROS), involves nicotin-
amide adenine dinucleotide phosphate
(NADPH)-dependent oxidases and lipid
peroxidation, and is associated morpho-
logically with the presence of shrunken,
electron-dense mitochondria (Figure 1).
Distinguishing it from many other forms
of regulated cell death, ferroptosis does
not require caspases (mediators ofapoptosis and pyroptosis), ATP depletion
or mitochondrial ROS generation (media-
tors of necroptosis), Bax/Bak (essential
mediators of mitochondrial outer mem-
brane permeabilization, MOMP), or eleva-
tions in intracellular Ca2+.
Ferroptosis was uncovered while
seeking an understanding of the mecha-
nism underlying the activity of erastin,
a small molecule that selectively kills
cells expressing oncogenic mutants of
RAS (Dolma et al., 2003). This quinazo-
line compound binds certain voltage-
dependent anion channels (VDACs) on
the mitochondrial outer membrane.
Moreover, short hairpin RNA (shRNA)
reagents targeting VDAC2 and VDAC3
rescue oncogenic RAS-expressing tumorcells from erastin (Yagoda et al., 2007;
Yang and Stockwell, 2008). In the current
paper, Dixon et al. (2012) show that
erastin binds the subunit of cell surface
amino acid transporters that import
cystine, which then presumably causes
reductions in glutathione, sensitizing
cells to ROS. Evidence that cystine
transport is critical to the mechanism of
erastin includes data from experiments
that either pharmacologically bypass
erastin-induced cysteine transport block
or that block cysteine transport with
other compounds such as sulfasalazine
and glutamate. The authors also sensi-
tized tumor cells to erastin by shRNA-
mediated knockdown of a subunit
(SLCA11) of amino acid transporters149, May 25, 2012 ª2012 Elsevier Inc. 963
Figure 1. Ferroptosis—Cell Death by Iron-Dependent, Oxidative Injury
Ferroptosis is proposed to result from overwhelming iron-dependent oxidative injury, probably involving
lipid peroxidation. The cellular factors responsible for generating ROS include NADPH-dependent
oxidases. Some of the pathways impacting cellular sensitivity to ferroptosis are depicted, including
regulators of iron homeostasis, RAS pathway induction of oxidase gene expression, and cystine
transport impacting glutathione synthesis. Erastin modulates both cystine transport and VDAC-medi-
ated NADH transport. Other chemical modulators are highlighted in red, including the newly reported
ferrostatin.and blunted erastin-mediated cytotox-
icity by overexpressing the transporter
subunit. Together, these data support
the conclusion that erastin inhibits
cysteine import. However, to definitively
determine whether cystine transport is
the critical cellular target of erastin that
explains its cytotoxic activity against
RAS-expressing cells, a thorough struc-
ture-activity relationship (SAR) analysis
is required using various erastin analogs,
including existing active versus inactive
enantiomers.
Considering that previous studies
have illustrated that chemical oxidants
induce cytotoxicity of RAS-transformed
cells (Trachootham et al., 2006), the
novelty of the proposed new cell death
mechanism is not that cystine-dependent
glutathione production is altered by
erastin but that this form of cell death
requires iron. Screening a mitochondria-
focused shRNA library revealed iron
regulatory protein 2 (IRB2) as a target
that promotes erastin-induced killing.
Conversely, knocking down expression
of the endogenous IRB2 antagonist964 Cell 149, May 25, 2012 ª2012 Elsevier InFBXL5 sensitized cells to erastin. IRB2 is
an RNA-binding protein that controls the
translation of a group of mRNAs involved
in iron homeostasis, decreasing iron
uptake by reducing transferrin receptor
expression and sequestering free Fe(II)
by inducing ferratin expression. These
and other experiments, such as reducing
erastin-induced cytotoxicity with shRNA
directed toward transferrin receptors,
suggest that the pool of labile iron
controls sensitivity to erastin. The authors
also showed a role for NADPH-depen-
dent oxidases that oncogenic RAS
upregulates, including NADPH oxidase
(NOX1), which interacts with protein
complexes that contain Fe/heme-binding
proteins.
Roles for iron in cell death have been
recognized for many years in brain injury
and neurodegeneration (Aracena et al.,
2006). For example, elevated levels of
iron are found in the substantia nigra of
patients with Parkinson’s disease and
have also been reported in Alzheimer’s
brains. Iron chelation shows neuroprotec-
tive effects in models of neurotoxicityc.induced by 6-hydroxydopamine and
MPP+ (dopaminergic neurons) and also
by amyloid-b peptide. Iron chelators
have also shown neuroprotective activity
in some animal models of neurotrauma.
Moreover, N-methyl-D-aspartate (NMDA)
receptors, mediators of L-glutamate-
induced neuronal cell death, are reported
to induce Fe(II) import into neurons.
Further, L-glutamate was reported previ-
ously to impact cystine transport in
neurons (Murphy et al., 1989), suggesting
that L-glutamate could have an erastin-
like effect. Dixon and colleagues also
show that an iron-chelating compound
suppresses L-glutamate-induced neu-
ronal cell death in vitro. Although the
evidence supporting a ferroptosis mecha-
nism in neuronal cell death is based only
on pharmacological agents with little
genetic validation of the importance of
the ferroptosis mechanism either in vitro
or in vivo, the authors open the door
for future studies by speculating that
neuronal excitotoxicty and erastin-trig-
gered cancer cell death share common
features that are consistent with ferropto-
sis. Based on the current evidence,
however, it is prudent to conclude that it
remains an open question whether ferrop-
tosis actually occurs in vivo under some
pathophysiological circumstances.
An interesting feature of cell death
mechanisms induced by erastin is an
apparent role for lipid oxidation. Among
the targets identified as enablers of era-
stin-induced cytoxicity of RAS-express-
ing tumor cells were genes encoding
enzymes involved in mitochondrial fatty
acid synthesis. Conversely, lipophilic anti-
oxidant compounds were shown to be
especially potent suppressors of cell
death induced by erastin as well as
another RAS synthetic lethal compound
that selectively kills cells expressing
activated RAS in an iron-dependent
manner but that does not interfere with
cystine transport. An intriguing possibility
is that ferroptosis involves production of a
specific class of cytotoxic lipids, a notion
reminiscent of the requirement for certain
sphingomyelin metabolites for Bax/Bak-
mediated MOMP (Chipuk et al., 2012).
A conundrum in the use of erastin as
a chemical probe for investigatingmecha-
nisms of ferroptosis is its reported binding
to at least two putative targets: VDAC2
and the SLC7A5 subunit of amino acid
transporters. Is it necessary for erastin to
bind both of these cellular targets to
enable ferroptosis? Previous studies
showed that erastin inhibits VDAC-
mediated transport of NADH into mito-
chondria, thus raising the possibility
that erastin’s effects on VDAC may help
to elevate cytosolic levels of NADPH
to support the activity of cytosolic
oxidases that generate lethal levels of
ROS (Yagoda et al., 2007; Yang and
Stockwell, 2008). Consequently, erastin
might promote ROS production both
by influencing the activity of NADPH-
requiring oxidases and by reducing
cystine-dependent glutathione produc-
tion via decreased cystine transport,
thereby lowering antioxidant defenses.
However, given that ROS have been
implicated in so many forms of cell death,
one wonders whether ‘‘pure’’ ferroptosis
is easily discerned, which is a question
that would potentially yield to single-cell
analysis rather than relying on bulk cell
populations.
The practical utility of chemical biology
efforts that have led to the discovery of
compounds such as erastin, which
promotes iron-dependent oxidative killingof RAS-expressing cancer cells, is yet to
be determined. Oncogenic RAS muta-
tions occur in 20% of human cancers,
but RAS itself has failed to yield to drug
discovery efforts, prompting interest in
downstream targets of the RAS pathway.
An analog of erastin (PRLX-93936) was
tested in phase I trials but was poorly
tolerated, raising concerns about thera-
peutic index (Ramanathan et al., 2010).
The FDA-approved drug Lanperisone
has been reported to kill RAS-trans-
formed tumor cells through a similar
iron- and ROS-dependent mechanism
(Shaw et al., 2011), suggesting a potential
drug repurposing opportunity. While
sulfasalazine (another approved medi-
cine) also inhibits cystine transport, its
potency is probably too weak to trigger
ferroptosis in vivo. More work is needed
toward understanding the mechanism(s)
of ferroptosis so that optimal targets can
be identified for future drug discovery
efforts.REFERENCES
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Tissues develop in confined volumes that can imposemechanical constraints on their growth, but it
is unclear how cells respond to these limits to regulate tissue size and shape. Two papers show that
overcrowding and cell deformation lead to the shedding of live cells to maintain homeostasis in
epithelial cell sheets.How tissuesacquire andmaintain their size
and shape is one of themysteries of devel-
opmental biology. In nature, tissues do notdevelop in isolation, but in the presence of
mechanical constraints imposed by their
surroundings. Theoretical studies suggestthat compressive forces could limit the
rate of cell growth, producing a system in
homeostasis in which cell proliferation149, May 25, 2012 ª2012 Elsevier Inc. 965
